Orgotein in equine navicular disease: a double blind study.
Authors: Coffman, Johnson, Tritschler, Garner, Scrutchfield
Journal: Journal of the American Veterinary Medical Association
Summary
# Editorial Summary: Orgotein in Equine Navicular Disease Navicular disease remains a significant cause of lameness in horses, and treatment options have historically been limited; this 1979 double-blind trial investigated whether orgotein, a superoxide dismutase with putative anti-inflammatory properties, might offer therapeutic benefit when administered directly into the navicular bursa. Fourteen horses with confirmed clinical and radiographic navicular disease were randomly assigned to receive either orgotein or placebo via juxtabursal injection, with investigators and handlers blinded to treatment allocation throughout. Three of seven orgotein-treated horses showed clinical improvement compared with none of the seven placebo recipients, a difference reaching statistical significance (P <0.05), suggesting that direct bursal delivery of orgotein may have genuine therapeutic effect in some cases. Whilst the response rate of approximately 43% indicates orgotein is not a universal solution, the positive findings warrant consideration of bursal anti-inflammatory strategies and suggest that intra-articular antioxidant therapy warrants further investigation in this notoriously difficult condition. Modern practitioners should note this early evidence whilst recognising that subsequent decades of research have expanded the evidence base considerably; however, the methodological rigour of this placebo-controlled approach remains a valuable benchmark for evaluating emerging navicular treatments.
Read the full abstract on PubMed
Practical Takeaways
- •Orgotein administered by juxtabursal injection shows modest but statistically significant efficacy for navicular disease (43% response rate), though a majority of treated horses still did not respond
- •This early evidence suggests orgotein may have a role in navicular management, but should not be relied upon as a primary or sole treatment given the high non-response rate
- •Double-blind design confirms genuine therapeutic effect beyond placebo, warranting further investigation into patient selection factors that predict responders
Key Findings
- •3 of 7 orgotein-treated horses responded to therapy versus 0 of 7 placebo-treated horses (P < 0.05)
- •43% response rate achieved with orgotein administered via juxtabursal injection in horses with confirmed clinical and radiographic navicular disease
- •Placebo group showed no clinical response despite identical disease presentation at baseline